In total, based on a financial auditor determination that these batches MAY expire before they are saleable, they had a financial justification to write off $70M of inventory - on prior financial statements. The inventory shelf life issue is not really new data, but recognizing it in financial reporting sounds bad...

...or you can consider that any testing that could extend the product shelf life, or any approval prior to shelf life expiration, means that for potential future sales of these batches, the cost of goods sold will be zero, which increases margins and profitability in future financial statements on those potential sales by the same amount... and by extension, again assuming the product is ultimately saleable, that makes the company more valuable in the future (to someone/some entity).

Not giving financial advise but my read on this is, without any other news pre-market, the market tomorrow will likely react to the first paragraph; but if you are a believer in CYDY and Leronlimab's future viability, that could create an opportunity.